Compare FUBO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | TTRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.1M | 298.8M |
| IPO Year | 2011 | 2025 |
| Metric | FUBO | TTRX |
|---|---|---|
| Price | $11.65 | $13.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $20.33 | $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 69.8K |
| Earning Date | 05-06-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,271,000.00 | N/A |
| Revenue This Year | $44.64 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10317.07 | N/A |
| 52 Week Low | $1.02 | $2.57 |
| 52 Week High | $14.54 | $14.39 |
| Indicator | FUBO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 72.88 |
| Support Level | $8.49 | $9.02 |
| Resistance Level | $11.68 | N/A |
| Average True Range (ATR) | 0.70 | 1.04 |
| MACD | 0.05 | 0.37 |
| Stochastic Oscillator | 55.07 | 83.21 |
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. The company operates in a single segment of the streaming business.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.